89bio, Inc. financial data

Symbol
ETNB on Nasdaq
Industry
Pharmaceutical Preparations
Location
142 Sansome Street, Second Floor, San Francisco, California
State of incorporation
Delaware
Fiscal year end
December 31
Latest financial report
Q1 2024 - May 9, 2024

Key Ratios

Label TTM Value / Value Unit Change %
Current Ratio 1.78 K % +89%
Debt-to-equity 12 % -52.4%
Return On Equity -34.8 % +31.5%
Return On Assets -31.1 % +23.4%

Shares

Label TTM Value / Value Unit Change %
Entity Common Stock, Shares Outstanding 98.4 M shares +88.4%
Common Stock, Shares, Outstanding 95.2 M shares
Entity Public Float 1.18 B USD +3767%
Common Stock, Value, Issued 95 K USD +30.1%
Weighted Average Number of Shares Outstanding, Basic 95.8 M shares +80.3%
Weighted Average Number of Shares Outstanding, Diluted 95.8 M shares +80.3%

Income Statement

Label TTM Value / Value Unit Change %
Research and Development Expense 147 M USD +77%
General and Administrative Expense 32.6 M USD +45.5%
Operating Income (Loss) -180 M USD -70.3%
Income (Loss) from Continuing Operations before Income Taxes, Noncontrolling Interest -161 M USD -53%
Income Tax Expense (Benefit) 97 K USD
Net Income (Loss) Attributable to Parent -165 M USD -56.7%
Earnings Per Share, Basic -2 USD/shares +9.5%
Earnings Per Share, Diluted -2 USD/shares +9.5%

Balance Sheet

Label TTM Value / Value Unit Change %
Cash and Cash Equivalents, at Carrying Value 218 M USD -38%
Marketable Securities, Current 345 M USD
Cash, Cash Equivalents, and Short-term Investments 562 M USD +16.9%
Assets, Current 575 M USD +16.4%
Property, Plant and Equipment, Net 37 K USD -52.6%
Operating Lease, Right-of-Use Asset 2.12 M USD +558%
Other Assets, Noncurrent 385 K USD +33.2%
Assets 577 M USD +16.8%
Accounts Payable, Current 15.4 M USD -8.22%
Employee-related Liabilities, Current 2.6 M USD +44.6%
Accrued Liabilities, Current 20.3 M USD +185%
Liabilities, Current 38.2 M USD +59.2%
Operating Lease, Liability, Noncurrent 1.64 M USD +1055%
Other Liabilities, Noncurrent 3.84 M USD
Liabilities 66.8 M USD +37.7%
Accumulated Other Comprehensive Income (Loss), Net of Tax -519 K USD -116%
Retained Earnings (Accumulated Deficit) -509 M USD -48%
Stockholders' Equity Attributable to Parent 511 M USD +14.5%
Liabilities and Equity 577 M USD +16.8%

Popular Metrics

Label TTM Value / Value Unit Change %
Net Cash Provided by (Used in) Operating Activities -39.7 M USD -32%
Net Cash Provided by (Used in) Financing Activities 21 M USD -93.5%
Net Cash Provided by (Used in) Investing Activities -79.9 M USD -2046%
Common Stock, Shares Authorized 200 M shares
Common Stock, Shares, Issued 95.2 M shares
Common Stock, Par or Stated Value Per Share 0 USD/shares
Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect -98.6 M USD -133%
Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents 218 M USD -38%
Interest Paid, Excluding Capitalized Interest, Operating Activities 679 K USD +25.3%
Deferred Tax Assets, Valuation Allowance 108 M USD +42.4%
Deferred Tax Assets, Gross 109 M USD +42.8%
Operating Lease, Liability 2.31 M USD +553%
Depreciation 9 K USD -35.7%
Payments to Acquire Property, Plant, and Equipment 4 K USD -42.9%
Comprehensive Income (Loss), Net of Tax, Attributable to Parent -165 M USD -57%
Lessee, Operating Lease, Liability, to be Paid 2.87 M USD +661%
Operating Lease, Liability, Current 702 K USD +311%
Lessee, Operating Lease, Liability, to be Paid, Year Two 917 K USD +396%
Lessee, Operating Lease, Liability, to be Paid, Year One 774 K USD +318%
Deferred Income Tax Expense (Benefit) 127 K USD
Lessee, Operating Lease, Liability, Undiscounted Excess Amount 555 K USD +2313%
Lessee, Operating Lease, Liability, to be Paid, Year Three 937 K USD +13286%
Preferred Stock, Shares Issued 0 shares
Current Income Tax Expense (Benefit) 3.74 M USD +19584%
Preferred Stock, Shares Authorized 10 M shares 0%
Unrecognized Tax Benefits 12.1 M USD +664%
Lessee, Operating Lease, Liability, to be Paid, Year Four 240 K USD
Additional Paid in Capital 1.02 B USD
Preferred Stock, Shares Outstanding 0 shares
Current State and Local Tax Expense (Benefit) 3 K USD +50%
Operating Leases, Future Minimum Payments, Due in Two Years 7 K USD -72%
Deferred Tax Assets, Net of Valuation Allowance 715 K USD +124%
Share-based Payment Arrangement, Expense 17.6 M USD +54%
Operating Leases, Future Minimum Payments Due 105 K USD -33.5%
Interest Expense 3.58 M USD -0.2%
Preferred Stock, Par or Stated Value Per Share 0 USD/shares 0%